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Abstract 
A young woman presenting with an ovarian immature teratoma (stage IA, grade 2) 
demonstrates the dilemma associated with the decision to withhold adjuvant 
chemotherapy of documented clinical utility in a setting where highly effective 
treatment is available should the cancer ultimately recur. 
Introduction 
It is well recognized that advances in the chemotherapeutic management of a number 
of cancers has resulted in highly meaningful improvement in survival, symptom control 
and overall quality-of-life for patients initially presenting with metastatic cancer or where 
there is recurrence of the malignant process following definitive local/regional therapy. 
The demonstrated utility of such therapy has led to the rational suggestion that 
individuals presenting with earlier stages of disease (e.g., cancer surgically documented to 
be confined to a single organ), but who posses known unfavorable clinical features (e.g., 
high-grade malignancy) might simply be observed, rather than receiving ‘standard’ 
adjuvant chemotherapy, with anti-neoplastic drug treatment being initiated only if there 
is subsequent evidence of disease recurrence. 
A recent patient seen in consultation highlights the dilemma that surrounds the 
decision to withhold adjuvant therapy in this specific clinical setting.  
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Case Report 
A 19-year-old female developed sudden onset of left-sided pelvic pain. An emergency ultrasound 
revealed the presence of a left adnexal mass. At laparoscopic surgery performed by an experienced 
gynecologic surgeon, a 4-cm mass lesion was removed, with the remainder of the peritoneal cavity 
appearing normal. Pathology revealed an immature teratoma (grade 2). Washings revealed no evidence 
of cancer. This interpretation was confirmed by a reference gynecologic pathologist at a tertiary care 
institution. The patient and her family had obtained several opinions regarding the need for adjuvant 
chemotherapy in this setting, with opinions ranging from the absolute requirement to administer three 
cycles of cisplatin, etoposide, bleomycin, to the suggestion that it was reasonable at this point in time to 
carefully observe the patient without systemic treatment, and only initiate cytotoxic therapy (with 
cisplatin, etoposide, bleomycin) if there was evidence of disease recurrence. 
Discussion 
Female germ cell tumors, like their counterparts in males, are among the most 
chemotherapy-sensitive of all human malignancies [1]. Even in the setting of cancer 
spread throughout the peritoneal cavity the combination of aggressive surgical 
cytoreduction (designed to remove all gross macroscopic disease) followed by cisplatin-
based chemotherapy is curative in most women found to have this cancer [1, 2]. 
The effectiveness of treatment in the advanced, metastatic, or recurrent disease 
settings, and the rational desire to avoid the risk of inducing infertility resulting from the 
administration of cytotoxic chemotherapy in a younger female population (most likely to 
develop this malignancy) prompt the logical and appropriate question of observation as a 
management strategy, rather than adjuvant chemotherapy in this setting [2]. 
However, it is well recognized that immature teratomas, like other non-dysgerminoma 
germ cell tumors, can be highly malignant and result in death, despite the overall 
effectiveness of treatment of advanced disease [1]. It is reasonable to argue that the 
administration of highly active chemotherapy in the adjuvant setting, where unrecognized 
microscopic cancer may be present, has the legitimate potential to substantially reduce, or 
even nearly eliminate the risk that recurrence will be experienced. 
In the case under discussion while the presence of ‘grade 2 features’ clearly placed this 
patient in a somewhat unfavorable prognostic category, it is genuinely uncertain if the 
benefits of early treatment outweigh the risk of toxicity, particularly considering the 
known favorable impact of subsequent therapy (if necessary). 
It is rational to conclude that the only satisfactory solution to the dilemma is full and 
very clear disclosure to the patient (and her family) regarding what is both known (e.g., 
effectiveness of chemotherapy in the metastatic and adjuvant settings; potential toxicities, 
both short-term and long-term) and uncertainties of the situation (e.g., absence of reliable 
data on the true magnitude of any increased risk associated with the strategy of 
observation rather than the administration of adjuvant treatment). Ultimately, after all 
available data have been presented, and questions have been asked and (to the fullest 
extent possible) answered by the oncologist, the patient (and her family) will need to 
make their own decision regarding what is the optimal management course. 
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